PRICING AND REIMBURSEMENT

Medical device companies are developing innovative technologies at a rapid pace. With CE marking, EU market access for some medical devices may be an option before other markets can be entered. However, selling in the European market is often hampered by national differences in coding, coverage and payment for new medical devices. Furthermore, Diagnosis Related Groups (DRGs) systems in various EU countries are regularly being reevaluated with potential impact on medical device sales.

In this complex environment, MedPass can assist you to ensure faster market access across Europe.

In many major European markets, the process for gaining reimbursement is characterized by a health technology assessment (HTA) approach whereby payer organizations evaluate new medical device technologies on the basis of their clinical value, cost-effectiveness and other health economic factors. Preparing for such an evaluation can be an awesome challenge. Protecting as long as possible of price level and reimbursement for established medical devices.

Accelerating EU market access for your medical device

MedPass will develop a reimbursement roadmap for your device through careful analysis of the disease management process in the target market. By helping you to determine precisely how your device fits into the current reimbursement situation. We can develop a reimbursement and funding strategy to encourage market adoption and ensure proper payment with a roadmap that will capitalize on short term opportunities and build for long term success. We then help you implement your reimbursement strategy. With over a decade of advanced reimbursement problem-solving to our credit, we know how to anticipate obstacles and avoid the many pitfalls that can compromise reimbursement approval.

MedPass International's team of expert reimbursement consultants is diversely qualified and problem-solving oriented. We are also well connected by maintaining close working relationships with key decision makers from health authorities, public health insurance organizations, evaluation committees, medical associations, key opinion leaders, and clinical experts in the relevant countries and therapeutic areas.

Services:

• Identification of favorable reimbursement environments Expertise in reimbursement environment,
• Examination of current payment rates with identification of potential coding Strategic analyses market access,
• Customized advices and understanding how a medical device can be reimbursed in each relevant market in Europe,
• Practical advice about how reimbursement applications are being assessed and which data can make the difference,
• Identification of reimbursement processes for innovative technologies.

Reimbursement Applications

Carrying out of formal applications procedure country per country (France: LPPR dossier, medical procedure creation CCAM), (Germany: OPS and NUB codes)
Pricing application dossier and support during negotiation with the authorities

Core value dossiers
"Generic dossier" preparation that can then be locally adapted to meet expectations from national authorities and/or payers organisms in the different countries.
Economic Modeling
Economic analyse adapted to the relevant expectation from the authorities.